Biotech Stocks Make NYSE Top Gainers October 20Th
Arcus Biosciences, Inc. (NYSE:RCUS ) makes the NYSE top gainer list as the Direxion Daily S&P Biotech Bull 3X (NYSE: LABU ) also makes the list today, trading at $236.65 +23.86 (+11.21%). Arcus Biosciences is trading at $24.25 +2.11 (+9.53%) on news, with a morning high of $24.70.
AdvertisementNews Highlights- Progression-free survival (PFS) for casdatifan plus anti-PD-1 in the first-line (1L) setting exceeded third-party benchmarks* for the approved anti-PD-1 plus anti-CTLA-4 regimen (ipilimumab plus nivolumab) and is similar to benchmarks for approved anti-PD-1 plus TKI regimens; the Phase 3 PEAK-20 study evaluating casdatifan plus ipilimumab and nivolumab is on track to start by year-end. PFS and overall survival (OS) in the second-line (2L) cohort evaluating casdatifan plus cabozantinib substantially exceeded benchmarks for cabozantinib monotherapy, including in patients who had previously progressed on TKIs; the ongoing Phase 3 PEAK-1 study is evaluating the same combination in the same patient population. An unprecedented nearly three-year median OS was reached in heavily pre-treated kidney cancer patients (majority third-line plus [3L+]) in the pooled monotherapy cohorts, exceeding the benchmark for the only approved HIF-2alpha inhibitor by more than one year; these data reinforce the potential for robust and durable HIF-2alpha inhibition to deliver a survival benefit across lines of therapy and support plans for a registrational trial to evaluate the combination of casdatifan plus tivozanib.
Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data at an investor event in New York City from the ARC-20 platform study, which is evaluating casdatifan, an investigational next-generation HIF-2alpha inhibitor, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma (ccRCC).
Full news
Research biotech stocks at the free stock directory at Investorideas
Learn more about becoming a featured annual biotech stock or be featured in a trading alert
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment